Drug Discovery Pilot Awards

The new Drug Discovery Pilot Award Program, jointly funded by the University of Rochester Medical Center and the Moulder Center for Drug Discovery Research at Temple University, is requesting applications for its second round of grant funding. The collaboration enables Rochester scientists to combine their knowledge of the underlying biology of disease with the ability of the medicinal chemists and pharmacologists at the Moulder Center to identify and create compounds suitable for medical research and eventual use in humans.

The Program will support two categories of research. The first will fund “early exploratory studies” and consist of grants to scientists that will allow them to conduct focused preliminary experiments and to access high throughput screening technologies that can rapidly evaluate and identify suitable chemical compounds. The grants can range from $4,000-8,000 and are expected to support studies conducted at Rochester only.

The program will also support “lead finding studies,” which will enable scientists to take their research a step further by confirming that a compound and its target are a match, producing “second generation” compounds with improved activity against that target, and testing whether these compounds have characteristics that are compatible with the human body. Up to $25,000 will be considered to support studies at Rochester, with Moulder support provided at no-cost, based on project needs and recommendations of Moulder Center leadership. 

Restrictions: URSMD faculty only (including non-tenure-track).  Faculty salary support is not permitted.

For more information about the Drug Discovery Pilot Award Program, and submission criteria and guidelines, click here. The submission deadline is November 2, 2012, NOT October 31st as indicated on the web site.

 

NIH Funding Acknowledgement ** Important ** All publications resulting from the utilization of CTSI resources are required to credit the CTSI grant by including the NIH FUNDING ACKNOWLEDGEMENT and must comply with the NIH Public Access Policy.